Nimble Therapeutics is collaborating with Genentech, a member of the Roche Group, to accelerate discovery and development of novel peptide-based medicines for targets across a range of diseases.
 
The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, chemical diversity, and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.
 
“We are excited to collaborate with a world class and well-respected organization such as Genentech to identify novel peptide therapeutics,” said Jigar Patel, chief executive officer, Nimble Therapeutics. “This partnership combines the strengths of our two organizations to potentially bring new medicines to patients.”
 
Under the terms of the agreement, Nimble will receive an undisclosed upfront payment and will be eligible for downstream milestone payments and royalties.